Leishmaniasis and various immunotherapeutic approaches.
Taslimi Y, Zahedifard F, Rafati S.
Parasitology. 2018 Apr;145(4):497-507. doi: 10.1017/S003118201600216X. Epub 2016 Dec 15.
Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani M, Farhoudi R.
Drug Des Devel Ther. 2017 Dec 22;12:25-40. doi: 10.2147/DDDT.S146521. eCollection 2018.
Visceral leishmaniasis: An overview of vaccine adjuvants and their applications.
Ratnapriya S, Keerti, Sahasrabuddhe AA, Dube A.
Vaccine. 2019 Jun 12;37(27):3505-3519. doi: 10.1016/j.vaccine.2019.04.092. Epub 2019 May 15.
Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review.
Kelleci K, Allahverdiyev A, Bağirova M, Ihlamur M, Abamor EŞ.
J Vector Borne Dis. 2023 Apr-Jun;60(2):125-141. doi: 10.4103/0972-9062.361179.
NKT cells in leishmaniasis.
Zamora-Chimal J, Hernández-Ruiz J, Becker I.
Immunobiology. 2017 Apr;222(4):641-646. doi: 10.1016/j.imbio.2016.11.014. Epub 2016 Dec 5.
Peptide Vaccines for Leishmaniasis.
De Brito RCF, Cardoso JMO, Reis LES, Vieira JF, Mathias FAS, Roatt BM, Aguiar-Soares RDDO, Ruiz JC, Resende DM, Reis AB.
Front Immunol. 2018 May 11;9:1043. doi: 10.3389/fimmu.2018.01043. eCollection 2018.
Immunotherapy for visceral leishmaniasis: A trapeze of balancing counteractive forces.
Mazire PH, Saha B, Roy A.
Int Immunopharmacol. 2022 Sep;110:108969. doi: 10.1016/j.intimp.2022.108969. Epub 2022 Jun 20.
Host Mast Cells in Leishmaniasis: Friend or Foe?
Naqvi N, Srivastava R, Selvapandiyan A, Puri N.
Trends Parasitol. 2020 Dec;36(12):952-956. doi: 10.1016/j.pt.2020.09.010. Epub 2020 Oct 12.
Overcoming roadblocks in the development of vaccines for leishmaniasis.
Kaye PM, Mohan S, Mantel C, Malhame M, Revill P, Le Rutte E, Parkash V, Layton AM, Lacey CJN, Malvolti S.
Expert Rev Vaccines. 2021 Nov;20(11):1419-1430. doi: 10.1080/14760584.2021.1990043. Epub 2021 Nov 2.
Vaccination in Leishmaniasis: A Review Article.
Abdellahi L, Iraji F, Mahmoudabadi A, Hejazi SH.
Iran Biomed J. 2022 Jan 1;26(1):1-35. doi: 10.52547/ibj.26.1.35.
